Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histamine as an adjunct to immunotherapy.

Peter Naredi1

  • 1Department of Surgery, Umea University Hospital, Umea, Sweden.

Seminars in Oncology
|June 18, 2002
PubMed
Summary

Adding histamine to cytokine therapy, like interleukin-2 and interferon-alpha, improves treatment for cancers such as melanoma and leukemia by restoring immune cell function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.

Annals of surgical oncology·2026
Same author

Accumulation of p62/sequestosome-1 in pancreatic cancer progression: association with inflammation and immune cell infiltration.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same author

Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.

Oncology letters·2024
Same author

Risks and use of ERCP during the diagnostic workup in a national cohort of biliary cancer.

Surgical endoscopy·2024
Same author

Adjunct mucin biomarkers MUC2+MUC5AC and MUC5AC+PSCA in a clinical setting identify and may improve correct selection of high-risk pancreatic lesions for surgery.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2024
Same author

Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models.

Gastro hep advances·2024

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Interleukin-2 (IL-2) and interferon-alpha (IFN-α) are used for malignancies like melanoma, leukemia, and renal cell carcinoma, but with suboptimal outcomes.
  • Tumor microenvironments contain monocytes and macrophages that suppress T cell and natural killer (NK) cell activity via reactive oxygen species (ROS).
  • ROS induce apoptosis in T cells and NK cells, limiting the efficacy of cytokine-based cancer therapies.

Purpose of the Study:

  • To investigate the potential of histamine to enhance the efficacy of cytokine therapy in treating specific cancers.
  • To determine if histamine can overcome the immunosuppressive effects of the tumor microenvironment on immune effector cells.

Main Methods:

  • In vitro and in vivo studies evaluating the effects of histamine on immune cell function in the presence of cytokines.
  • Clinical trials assessing the safety and efficacy of combined histamine and cytokine therapy for metastatic malignant melanoma, acute myelogenous leukemia, and renal cell carcinoma.

Main Results:

  • Histamine was found to abrogate the suppressive effects of monocytes and macrophages on T cells and NK cells.
  • The addition of histamine restored the cytotoxic activity of these immune cells.
  • Clinical trials demonstrated that combining histamine with cytokine therapy is safe and effective for the studied malignancies.

Conclusions:

  • Histamine can optimize cytokine therapy by counteracting tumor-associated immune suppression.
  • Combination therapy with histamine and cytokines shows promise for improving outcomes in metastatic malignant melanoma, acute myelogenous leukemia, and renal cell carcinoma.
  • Further clinical evaluation of histamine in cytokine-based cancer treatment regimens is warranted.

Related Experiment Videos